hcp.mykybella.comFOR HEALTHCARE PROFESSIONALS | KYBELLA® HCP

✖ See our new privacy terms at https://privacy.abbvie/.This site is intended for US healthcare professionals. IMPORTANT SAFETY INFORMATION PRESCRIBING INFORMATION FOR CONSUMERS ABOUT SUBMENTAL FULLNESS ABOUT KYBELLA KYBELLA ® CLINICAL STUDY DESIGN CLINICAL RESULTS SAFETY PROFILE MECHANISM OF ACTION ABOUT TREATMENT BEFORE & AFTER FAQ s TRAINING SETUP ACCOUNT Close Nav Button × Card Title ABOUT KYBELLA® The first-of-its-kind FDA-approved injectable, KYBELLA ® is a nonsurgical option to improve the appearance of submental fullness in adults. MORE Card Title BEFORE & AFTERS See the noticeable results and improved chin profile of patients treated with KYBELLA ® . Individual results may vary. VIEW BEFORE & AFTER See results of patients treated with KYBELLA ® injection. Individual results may vary. VIEW INDIVIDUALLY TAILORED* KYBELLA® INJECTIONS INDIVIDUALLY TAILORED * KYBELLA ® INJECTIONS For adults with moderate to severe submental fat (double chin): KYBELLA ® permanently destroys fat cells in the treatment area under the chin for an improved profile. 1 * Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart. 1 MORE GET TRAINED TODAY Register to watch the Online Training Video to become a trained KYBELLA ® injector. REGISTER INDICATION KYBELLA ® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA ® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS KYBELLA ® is contraindicated in the presence of infection at the injection sites. WARNINGS AND PRECAUTIONS Marginal Mandibular Nerve Injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA ® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. Dysphagia Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA ® in patients with current or prior history of dysphagia as treatment may exacerbate the condition. Injection Site Hematoma/Bruising In clinical trials, 72% of subjects treated with KYBELLA ® experienced hematoma/bruising. KYBELLA ® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures To avoid the potential of tissue damage, KYBELLA ® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury. Injection Site Alopecia Cases of injection site alopecia have been reported with administration of KYBELLA ® . Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution. Injection Site Ulceration, Necrosis, and Infection Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration, necrosis, and infection have been reported with administration of KYBELLA ® . Some cases of injection site infection have included cellulitis and abscess requiring antibiotic treatment and incision and drainage. Do not administer KYBELLA ® into affected area until complete resolution. ADVERSE REACTIONS The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration. Please see KYBELLA ® full Prescribing Information . Reference: 1. KYBELLA ® Prescribing Information, March 2023. Prescribing Information Terms of Use Corporate Site Contact Us Privacy Notice Cookies Settings Your Privacy Choices © 2024 AbbVie. All rights reserved. KYBELLA ® and its design are trademarks of Allergan Sales, LLC, an AbbVie company. US-FA-00493 01/24 025393 US-FA-00493 01/24 025393 US-FA-00493 01/24 025393 AbbVie may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, cookies”). We use this data for multiple purposes, including for online targeted advertising (advertisements... Read More Read Less COOKIES SETTINGS MANAGE CHOICES REJECT ALL ACCEPT...